newsfilter
← Latest News
GlobeNewswire·

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia (AML)Investigational New